Last 12 months
Inside the activity.
0 purchase rows · 6 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2019 Filed Apr 2, 2019 21:05 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 85 | $80.59 Strike: $0.00 | $6,850.15 |
DisclosureSEC source: 0001179110-19-004524 · edgar.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,389 Underlying: Common Stock · 85 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 17:05 UTC |
LIDDY EDWARD MDirector
|
GrantStock Equivalent Units · Derivative | 403 | $80.59 Strike: $0.00 | $32,477.77 |
DisclosureSEC source: 0001179110-19-004526 · edgar.xml · derivative · entry 1 LIDDY EDWARD M · CIK 0001188983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,459 Underlying: Common Stock · 403 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 21:06 UTC |
RAPP EDWARD JDirector
|
GrantStock Equivalent Units · Derivative | 421 | $80.59 Strike: $0.00 | $33,928.39 |
DisclosureSEC source: 0001179110-19-004527 · edgar.xml · derivative · entry 1 RAPP EDWARD J · CIK 0001171780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,907 Underlying: Common Stock · 421 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 20:34 UTC |
Durkin Brian LVP, Controller
|
SaleCommon Stock, $0.01 par value | 475 | $79.69 | $37,852.75 |
DisclosureSEC source: 0001179110-19-004224 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,121 Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 21:53 UTC |
Schumacher Laura JVice Chairman
|
SaleCommon Stock, $0.01 par value | 25,000 | $80.00 | $2,000,000.00 |
DisclosureSEC source: 0001179110-19-003945 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,838 Read SEC document |
| March 05, 2019 Filed Mar 6, 2019 22:03 UTC |
SALEKI-GERHARDT AZITAEVP, Operations
|
SaleCommon stock, $0.01 par value | 15,797 | $79.03 | $1,248,479.56 |
DisclosureSEC source: 0001179110-19-003445 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,312 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.77 to $79.31, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:53 UTC |
ALBAN CARLOSVice Chairman
|
Tax withholdingCommon Stock, $0.01 par value | 24,125 | $79.41 | $1,915,766.25 |
DisclosureSEC source: 0001179110-19-003072 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,877 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:54 UTC |
CHASE WILLIAM JEVP, Finance & Administration
|
Tax withholdingCommon stock, $0.01 par value | 27,276 | $79.41 | $2,165,987.16 |
DisclosureSEC source: 0001179110-19-003074 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Finance & Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,152 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:54 UTC |
Durkin Brian LVP, Controller
|
Tax withholdingCommon stock, $0.01 par value | 758 | $79.41 | $60,192.78 |
DisclosureSEC source: 0001179110-19-003077 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,596 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 16:55 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
Tax withholdingCommon stock, $0.01 par value | 72,925 | $79.41 | $5,790,974.25 |
DisclosureSEC source: 0001179110-19-003079 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,923 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:55 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
Tax withholdingCommon stock, $0.01 par value | 22,956 | $79.41 | $1,822,935.96 |
DisclosureSEC source: 0001179110-19-003080 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,763 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 16:56 UTC |
Michael Robert A.SVP, Chief Financial Officer
|
Tax withholdingCommon stock, $0.01 par value | 3,206 | $79.41 | $254,588.46 |
DisclosureSEC source: 0001179110-19-003084 · edgar.xml · nonDerivative · entry 1 Michael Robert A. · CIK 0001699914 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,913 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:57 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
Tax withholdingCommon stock, $0.01 par value | 12,345 | $79.41 | $980,316.45 |
DisclosureSEC source: 0001179110-19-003086 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,515 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:58 UTC |
SALEKI-GERHARDT AZITAEVP, Operations
|
Tax withholdingCommon stock, $0.01 par value | 12,569 | $79.41 | $998,104.29 |
DisclosureSEC source: 0001179110-19-003089 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,109 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:58 UTC |
Schumacher Laura JVice Chairman
|
Tax withholdingCommon stock, $0.01 par value | 24,275 | $79.41 | $1,927,677.75 |
DisclosureSEC source: 0001179110-19-003091 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,838 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:59 UTC |
SEVERINO MICHAELVice Chairman
|
Tax withholdingCommon stock, $0.01 par value | 26,710 | $79.41 | $2,121,041.10 |
DisclosureSEC source: 0001179110-19-003095 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,857 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:00 UTC |
Stewart Jeffrey RyanSVP, US Commercial Operations
|
Tax withholdingCommon stock, $0.01 par value | 6,907 | $79.41 | $548,484.87 |
DisclosureSEC source: 0001179110-19-003097 · edgar.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,752 Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:16 UTC |
Durkin Brian LVP, Controller
|
GrantOption (right to buy) · Derivative | 11,682 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001179110-19-002360 · edgar.xml · derivative · entry 6 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,682 Underlying: Common Stock · 11,682 shares Expires 2029-02-20 F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 3,894 on February 21, 2020, 3,894 on February 21, 2021, and 3,894 on February 21, 2022. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:16 UTC |
Durkin Brian LVP, Controller
|
GrantCommon stock, $0.01 par value | 576 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002360 · edgar.xml · nonDerivative · entry 4 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,354 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:16 UTC |
Durkin Brian LVP, Controller
|
GrantCommon stock, $0.01 par value | 1,074 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002360 · edgar.xml · nonDerivative · entry 3 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,869 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:16 UTC |
Durkin Brian LVP, Controller
|
GrantCommon stock, $0.01 par value | 874 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002360 · edgar.xml · nonDerivative · entry 2 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,159 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:16 UTC |
Durkin Brian LVP, Controller
|
GrantCommon stock, $0.01 par value | 1,213 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002360 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,464 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:17 UTC |
Donoghoe NicholasSVP, Enterprise Innovation
|
GrantOption (right to buy) · Derivative | 32,710 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001179110-19-002362 · edgar.xml · derivative · entry 1 Donoghoe Nicholas · CIK 0001762951 · SVP, Enterprise Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,710 Underlying: Common Stock · 32,710 shares Expires 2029-02-20 F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,904 on February 21, 2020, 10,903 on February 21, 2021, and 10,903 on February 21, 2022. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:17 UTC |
Stewart Jeffrey RyanSVP, US Commercial Operations
|
GrantOption (Right to buy) · Derivative | 25,700 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001179110-19-002363 · edgar.xml · derivative · entry 5 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,700 Underlying: Common Stock · 25,700 shares Expires 2029-02-20 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,567 on February 21, 2020, 8,566 on February 21, 2021, and 8,567 on February 21, 2022. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:17 UTC |
Stewart Jeffrey RyanSVP, US Commercial Operations
|
GrantCommon stock, $0.01 par value | 2,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002363 · edgar.xml · nonDerivative · entry 4 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,659 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:17 UTC |
Stewart Jeffrey RyanSVP, US Commercial Operations
|
GrantCommon stock, $0.01 par value | 3,909 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002363 · edgar.xml · nonDerivative · entry 3 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,689 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:17 UTC |
Stewart Jeffrey RyanSVP, US Commercial Operations
|
GrantCommon stock, $0.01 par value | 3,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002363 · edgar.xml · nonDerivative · entry 2 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,780 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:17 UTC |
Stewart Jeffrey RyanSVP, US Commercial Operations
|
GrantCommon stock, $0.01 par value | 5,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002363 · edgar.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,135 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 17:18 UTC |
Michael Robert A.SVP, Chief Financial Officer
|
GrantOption (Right to buy) · Derivative | 54,517 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001179110-19-002364 · edgar.xml · derivative · entry 5 Michael Robert A. · CIK 0001699914 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,517 Underlying: Common Stock · 54,517 shares Expires 2029-02-20 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 18,173 on February 21, 2020, 18,172 on February 21, 2021, and 18,172 on February 21, 2022. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 17:18 UTC |
Michael Robert A.SVP, Chief Financial Officer
|
GrantCommon stock, $0.01 par value | 1,485 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002364 · edgar.xml · nonDerivative · entry 4 Michael Robert A. · CIK 0001699914 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,119 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 17:18 UTC |
Michael Robert A.SVP, Chief Financial Officer
|
GrantCommon stock, $0.01 par value | 1,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002364 · edgar.xml · nonDerivative · entry 3 Michael Robert A. · CIK 0001699914 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,634 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 17:18 UTC |
Michael Robert A.SVP, Chief Financial Officer
|
GrantCommon stock, $0.01 par value | 1,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002364 · edgar.xml · nonDerivative · entry 2 Michael Robert A. · CIK 0001699914 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,924 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 17:18 UTC |
Michael Robert A.SVP, Chief Financial Officer
|
GrantCommon stock, $0.01 par value | 2,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002364 · edgar.xml · nonDerivative · entry 1 Michael Robert A. · CIK 0001699914 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,229 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:18 UTC |
SALEKI-GERHARDT AZITAEVP, Operations
|
GrantOption (Right to buy) · Derivative | 34,267 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001179110-19-002365 · edgar.xml · derivative · entry 7 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,267 Underlying: Common Stock · 34,267 shares Expires 2029-02-20 F7 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,423 on February 21, 2020, 11,422 on February 21, 2021, and 11,422 on February 21, 2022. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:18 UTC |
SALEKI-GERHARDT AZITAEVP, Operations
|
GrantCommon stock, $0.01 par value | 4,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002365 · edgar.xml · nonDerivative · entry 4 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,678 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:18 UTC |
SALEKI-GERHARDT AZITAEVP, Operations
|
GrantCommon stock, $0.01 par value | 7,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002365 · edgar.xml · nonDerivative · entry 3 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,397 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:18 UTC |
SALEKI-GERHARDT AZITAEVP, Operations
|
GrantCommon stock, $0.01 par value | 7,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002365 · edgar.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,227 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:18 UTC |
SALEKI-GERHARDT AZITAEVP, Operations
|
GrantCommon stock, $0.01 par value | 9,835 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002365 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,147 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:19 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
GrantOption (right to buy) · Derivative | 30,763 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001179110-19-002367 · edgar.xml · derivative · entry 5 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,763 Underlying: Common Stock · 30,763 shares Expires 2029-02-20 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,255 on February 21, 2020, 10,254 on February 21, 2021, and 10,254 on February 21, 2022. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:19 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
GrantCommon stock, $0.01 par value | 4,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002367 · edgar.xml · nonDerivative · entry 4 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,860 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:19 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
GrantCommon stock, $0.01 par value | 6,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002367 · edgar.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,755 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:19 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
GrantCommon stock, $0.01 par value | 7,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002367 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,915 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:19 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
GrantCommon stock, $0.01 par value | 9,835 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002367 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,835 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:19 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
GrantOption (Right to buy) · Derivative | 49,065 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001179110-19-002368 · edgar.xml · derivative · entry 6 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,065 Underlying: Common Stock · 49,065 shares Expires 2029-02-20 F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,355 on February 21, 2020, 16,355 on February 21, 2021, and 16,355 on February 21, 2022. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:19 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
GrantCommon stock, $0.01 par value | 6,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002368 · edgar.xml · nonDerivative · entry 4 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,719 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:19 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
GrantCommon stock, $0.01 par value | 11,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002368 · edgar.xml · nonDerivative · entry 3 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,164 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:19 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
GrantCommon stock, $0.01 par value | 14,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002368 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,434 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:19 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
GrantCommon stock, $0.01 par value | 19,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002368 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,399 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:20 UTC |
ALBAN CARLOSVice Chairman
|
GrantOption (right to buy) · Derivative | 62,305 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001179110-19-002369 · edgar.xml · derivative · entry 6 ALBAN CARLOS · CIK 0001474632 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,305 Underlying: Common Stock · 62,305 shares Expires 2029-02-20 F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,769 on February 21, 2020, 20,768 on February 21, 2021, and 20,768 on February 21, 2022. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:20 UTC |
ALBAN CARLOSVice Chairman
|
GrantCommon stock, $0.01 par value | 8,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002369 · edgar.xml · nonDerivative · entry 4 ALBAN CARLOS · CIK 0001474632 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,002 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.